This proposal outlines a project to identify new business development opportunities in medical nutrition in the US for Company X. It will involve qualitative research with a network of 30 Key Innovation Leaders with expertise in medical nutrition to gain insights on emerging areas, technologies, products and business models. The objectives are to seek opportunities like acquisitions, partnerships, licensing and joint ventures that can drive growth and redefine the medical nutrition field. The research will assess disruptive innovations, evolving markets, and companies that may be interested in opportunities to collaborate. The goal is to provide Company X with strategic options to develop new lines of business.

1.
Sample
Proposal:
Identifying
New
Business
Development
Opportunities
In
Medical
Nutrition
(U.S.
Focus)
February
24,
2017

2. 2
Dear
Jim,
Per
our
conversations,
Harrison
Hayes
has
incorporated
valuable
feedback
from
Company
‘X’
and
is
pleased
to
present
this
proposal,
‘Identifying
New
Business
Development
Opportunities
In
Medical
Nutrition’.
This
proposal
is
designed
to
assist
Company
‘X’
in
exploring
and
identifying
new
offerings
that
will
drive
growth
within
Company
‘X’
‘s
U.S.
medical
nutrition
business.
We
will
seek
to
unlock
new
business
development
opportunities
via
acquisition,
partnering,
licensing
and
joint
ventures
that
will
redefine
medical
nutrition
and
propel
Company
‘X’’s
growth
trajectory
in
the
U.S.
In
this
proposal,
we
will
review
the
objectives,
scope,
qualitative
research
and
ideation
methodology
of
this
project.
We
will
also
examine
additional
detail
regarding
the
ideation
methodology
that
Harrison
Hayes
will
utilize
to
obtain
unique
insights
into
identifying
disruptive
innovation
and
white
space
opportunities
particular
to
the
medical
nutrition
businesses.
We
are
highly
confident
that
our
ideation
methodology
and
insightful
results
will
exceed
your
expectations.
To
complement
our
work
on
this
project,
Harrison
Hayes
will
rely
on
a
dynamic
network
of
KILs
(Key
Innovation
Leaders)
who
have
deep
domain
expertise
and
are
well
respected
in
their
specific
disciplines.
This
assures
that
our
research,
ideation
and
points
of
view
are
of
the
highest
value.
We
welcome
your
suggestions
and
comments
and
are
looking
forward
to
a
great
working
relationship.
Sincerely,
Bill
Smith
Managing
Director
Harrison
Hayes,
LLC

3. 3

4. 4
Extrinsic)Innovation)Networks:)The)Closed)Innovation)Network)of)KILs)
!
The!Breakthrough!Innovation!and!Ideation!Methodology:!Uncovering!New!business!Development!Opportunities!
In!Medical!Nutrition!
Floyd)H.)
Chilton)
PhD)
Chanda)K.)Sen)
PhD)
Rachelle)S.)Doody)
MD,)PhD)
Alice)Ammerman)
PhD)
Molly)McMahon)
MD))
What)do)you)see)as)the)major)
research)breakthroughs)and/or)
product)and/or)new)business)model)
applications)inNluencing)the)
development)of)medical)nutrition?)In)
what)speciNic)disease)areas?)In)what)
speciNic)types)of)healthcare,)medicine,)
device)markets?)
Exploratory))
Questions)
Harrison)Hayes)SMEs)
moderate)and)
populate)the)forum)
with)questions)based)
on)exchanges)
between)members)
Participation)is)high)
due)to)each)member)
gaining)valuable)
feedback)from)others)
in)the)group.))Spirited)
exchanges)are)
encouraged)to)drive)
deep)understandings.)
Closed)Innovation)forum)
creates)a)sense)of)
commonality)leading)to)
freer)communication)and)
sharing)of)ideas)and)
concepts)
Fluid,)continuous)discussion)
allows)for)deep)insights)not)
found)in)focus)groups)or)
other)research)methods))
All)30)KILs)will)participate)in)a)closed)
innovation)network)forum)moderated)
and)populated)by)Harrison)Hayes)SMEs)

5. 5
RESEARCH
&
IDEATION
OBJECTIVES
The
primary
objective
of
this
research
project
is
to
seek
new
business
development
opportunities
to
drive
growth
and
redefine
the
medical
nutrition
ecosystem.
This
research
will
also
help
to
provide
Company
‘X’
with
a
stronger,
more
viable
platform
for
the
development
of
new
lines
of
business
with
strategic
innovation
and
integration
potential.
To
obtain
this
data,
Harrison
Hayes
will
focus
on
the
assessment
in
the
following
areas.
The
following
includes
a
sample
of
areas
of
assessment:
• Disruptive
innovation
(new)
product
potential
and
related
ideation
development
utilizing
our
technology
scouting
and
proprietary
Transforium
deal
flow
database.
• Emerging
medical
nutrition
business
models,
applications,
market
opportunities.
Evolutionary,
Revolutionary
and
Disruptive
landscape
analysis.
• Emerging
aging
medical
nutrition
business
models
and
identify
companies
that
are
interested
in
acquisition
or
licensing/partnering
opportunities.
• Emerging
brain
health
medical
nutrition
market
opportunities
and
identify
companies
that
are
interested
in
acquisition
or
licensing/partnering
opportunities.
• Emerging
chronic
illness
and
rare
disease
medical
nutrition
market
opportunities
and
identify
companies
that
are
interested
in
acquisition
or
licensing/partnering
opportunities.
• Emerging
critical
care
and
surgery
medical
nutrition
market
opportunities
and
identify
companies
that
are
interested
in
acquisition
or
licensing/partnering
opportunities.
• Emerging
food
allergy
medical
nutrition
market
opportunities
and
identify
companies
that
are
interested
in
acquisition
or
licensing/partnering
opportunities.
• Emerging
gastro-­‐intestinal
medical
nutrition
market
opportunities
and
identify
companies
that
are
interested
in
acquisition
or
licensing/partnering
opportunities.
• Emerging
malnutrition
medical
nutrition
market
opportunities
and
identify
companies
that
are
interested
in
acquisition
or
licensing/partnering
opportunities.
• Emerging
obesity
medical
nutrition
market
opportunities
and
identify
companies
that
are
interested
in
acquisition
or
licensing/partnering
opportunities.

6. 6
• Emerging
pediatric
medical
nutrition
market
opportunities
and
identify
companies
that
are
interested
in
acquisition
or
licensing/partnering
opportunities.
• Emerging
immuno-­‐oncology
medical
nutrition
market
opportunities
and
identify
companies
that
are
interested
in
acquisition
or
licensing/partnering
opportunities.
• Potential
mergers/acquisition;
partnerships;
collaborations;
alliances,
including
an
adjacent
market
(and
proximity
mapping)
analysis
• Divergent
and
convergent
white
space
and
business
model
opportunities
within
rare
and
ultra
rare
disease
therapies.
• Issues
and
challenges
(e.g.
regulatory,
competitive,
market
entry)
surrounding
the
medical
nutrition
marketplace
and
how
these
may
impact
our
findings.

7. 7
BACKGROUND
Recently,
the
United
States
has
seen
a
shrinking
gap
between
food
and
medicine.
There
appears
to
be
a
growing
trend
at
the
intersection
between
food
and
life
science
companies,
yet
it
has
not
been
definitely
determined
where
the
market
may
lead.
The
role
of
nutrition
is
entering
a
new
stage
of
discovery
and
innovation
–
not
just
in
addressing
nutritional
gaps
but
with
potentially
direct
therapeutic
impacts
–
that
is
changing
the
management
of
health
and
forging
an
increasingly
integral
role
in
the
management
of
health
across
the
human
life
cycle.
Company
‘X’
has
a
comprehensive
range
of
products
that
help
correct
or
improve
nutritional
status
that
are
important
–
and
in
some
cases
–
clinically
proven
to
be
a
vital
part
of
recovery
or
health
management.
Now,
new
opportunities
are
emerging
based
upon
scientific
advances
(omics)
being
made
about
both
the
nature
of
disease
and
the
potential
of
nutritionally
related
innovations
to
directly
impact
them
in
a
clinically
proven
way,
with
a
known
mode
of
action.
This
creates
the
potential
to
bring
forward
innovations
with
a
more
direct
and
clinically
proven
therapeutic
impact.
Nutrition
is
of
central
importance
to
the
treatment
of
various
diseases
and
health
conditions,
just
as
malnourishment
is
largely
responsible
for
their
prevalence.
In
recent
decades,
great
emphasis
has
been
placed
on
the
importance
of
nutrition
and
a
healthy
diet,
especially
in
hospital
settings,
since
malnutrition
is
a
widely
presented
problem
and
an
appropriate
dietary
plan
can
shorten
the
treatment
period
and
hence
the
duration
of
a
patient’s
hospitalization.1
Clinical
Nutrition
for
Medical
Conditions
Medical
Nutrition
A
new
era
of
personalized
healthy
eating
to
prevent
or
even
treat
disease
is
on
the
horizon,
say
nutrition
science
researchers,
who
see
this
as
a
key
part
of
the
global
effort
to
combat
chronic
preventable
diseases
that
can
be
related
to
diet,
such
as
cardiovascular
illness,
Type
2
diabetes
and
some
cancers.
These
types
of
noncommunicable
diseases
are
the
top
cause
of
death
worldwide,

8. 8
according
to
the
World
Health
Organization
(WHO),
killing
38
million
people
annually.
To
develop
more
individualized,
targeted
dietary
guidelines
and
therapeutic
nutrition
options,
researchers
are
working
to
understand
the
crucial
interactions
between
food
and
the
human
body.2
Rare
Diseases
Food
scientists
and
nutrition
researchers
around
the
United
States
are
catching
on
to
this
medical
nutrition
trend,
especially
in
rare
diseases.
Jeffrey
Blumberg
is
a
Tufts
University
nutrition
scientist
who
says
dietary
guidance
targeted
to
your
precise
genetic
makeup
is
the
wave
of
the
future.
Mark
Heiman
is
the
Chief
scientific
officer
of
MicroBiome
Therapeutics,
which
is
developing
health-­‐
boosting
nutritional
therapies
that
increase
the
variety
of
gut
microorganisms.
Microbiome
therapeutics
have
the
potential
to
address
the
underlying
causes
of
many
types
of
diseases
by
restoring
the
gut
microbiota
to
a
healthy
state.
This
healthy
state
can
be
disrupted
by
different
health
conditions
such
as
trauma
or
even
drugs.2
Dr.
Dean
Ornish,
Creator
of
a
renowned
program
for
reversing
cardiac
disease,
believes
dietary
changes
will
continue
to
be
key
to
a
healthy
heart.
Steven
Schwartz,
Ohio
State
University
food
scientist,
is
working
on
functional
food
products
to
help
prevent
cancer
and
other
illnesses.
Robert
Zeigler,
Director
general
of
the
International
Rice
Research
Institute,
is
coordinating
the
Golden
Rice
project
designed
to
raise
vitamin
A
levels
in
developing
nations.
Immuno-­‐oncology
Malnutrition
is
a
frequent
problem
in
cancer
patients,
which
leads
to
prolonged
hospitalization,
a
higher
degree
of
treatment-­‐related
toxicity,
reduced
response
to
cancer
treatment,
impaired
quality
of
life
and
a
worse
overall
prognosis.
The
attitude
towards
this
issue
varies
considerably
and
many
malnourished
patients
receive
inadequate
nutritional
support.
Evidence
from
the
literature
suggests
that
nutritional
screening
should
be
performed
using
validated
tools
(the
Nutritional
Risk
Screening
2002
[NRS
2002],
the
Malnutrition
Universal
Screening
Tool
[MUST],
the
Malnutrition
Screening
Tool
[MST]
and
the
Mini
Nutritional
Assessment
[MNA]),
both
at
diagnosis
and
at
regular
time
points
during
the
course
of
disease
according
to
tumor
type,
stage
and
treatment.
Nutritional
intervention
should
be
actively
managed
and
targeted
for
each
patient;
it
should
comprise
personalized
dietary
counseling
and/or
artificial
nutrition
according
to
spontaneous
food
intake,
tolerance
and
effectiveness.
Nutritional
support
may
be
integrated
into
palliative
care
programs.
“Alternative
hypocaloric
anti-­‐cancer
diets”
(e.g.
macrobiotic
or
vegan
diets)
should
not
be
recommended
as
they
may
worsen
nutritional
status.3
Medical
Nutrition
covers
specific
dietary
needs
of
patients
suffering
from
illnesses
or
specific
disease
states
including
Inborn
Errors
of
Metabolism,
Paediatric
Care
&
food
allergy,
Acute
Care
(including
critically
ill,
swallowing
disorders
and
cancer),
as
well
as
Metabolic
and
Obesity
care.
Our
Medical
Nutrition
products
are
recommended
by
healthcare
professional
and
used
in
hospitals,
nursing
homes,
and
in
home
care.
Aging
The
United
States
is
a
quickly
aging
nation,
which
will
only
stimulate
the
growth
of
the
nutraceutical
market.
Currently,
roughly
12.7%
of
the
American
population
is
over
the
age
of
65,
and
this
percentage
is
expected
to
increase
to
over
19%
by
the
year
2030
as
the
Baby
Boomer
population
reaches
retirement
age.4
As
people
age,
the
human
body
undergoes
several
changes,
many
of
which
can
be
addressed
through
the
use
of
nutraceuticals.
A
range
of
nutrition-­‐based
technology
platforms
are
being
developed,
aiming
to
bring
forward
clinically
proven
innovations,
specifically
in
the
areas
of
brain
and
gastrointestinal
health.
In
brain

9. 9
health
and
Alzheimer’s
disease
for
example,
further
clinical
trials
are
underway
of
a
product
that
helps
the
brain
to
process
glucose
needed
for
effective
brain
function.
Medical
Nutrition
Conditions
Diseases
in
Which
Clinical
Nutrition
may
be
indicated
Company
‘X’
is
focused
on
advancing
nutritional
therapy
to
change
the
course
of
health
–
for
people,
patients
and
our
partners
in
healthcare.
They
are
seeking
whitespace
opportunities
to
drive
growth
and
redefine
medical
nutrition
offerings
in
the
United
States.
There
is
a
compelling
opportunity
to
create
a
space
“where
nutrition
becomes
therapy.”
By
offering
innovative,
medical
nutritional
products,
Company
‘X’
can
enable
consumers
to
manage
their
day-­‐to-­‐day
individual
health
needs
through
nutrition.

10. 10
References
1. Clinical
Nutrition
in
Practice.
Katsilambros
N,
Dimosthenopoulos
C,
Kontogianni
M,
et
al.
Athens
University
School
of
Medicine,
Laiko
University
Hospital.
Blackwell
Publishing
Ltd.
West
Sussex,
United
Kingdom;
2010.
2. Current
Series:
Nutrition
Innovation.
Food
Future2050.
Accessed
at
http://futurefood2050.com/interviews/nutrition-­‐innovation/
on
February
13,
2017.
3. Caccialanza
R,
Pedrazzoli
P,
Cereda
E,
et
al.
Nutritional
Support
in
Cancer
Patients:
A
Position
Paper
from
the
Italian
Society
of
Medical
Oncology
(AIOM)
and
the
Italian
Society
of
Artificial
Nutrition
and
Metabolism
(SINPE).
J
Cancer.
2016;7(2):131-­‐5.
4. Is
Healthcare
Recession
Proof?
An
Analysis
of
the
Status
of
the
Healthcare
Industry
in
Some
Developed
Nations.
Frost
and
Sullivan.
14
June
2010.

11. 11
PROJECT
SCOPE
Harrison
Hayes
will
assist
Company
‘X’
in
seeking
whitespace
opportunities
to
drive
growth
and
redefine
medical
nutrition
offerings
in
the
United
States.
The
scope
of
this
project
is
domestic.
METHODOLOGY
Primary
Research
The
Key
Innovation
Leader
(KIL)
questionnaire
will
be
developed
through
a
collaborative
effort
with
Company
‘X’
in
order
to
ensure
that
the
focus
of
this
project
is
being
addressed.
The
questionnaire
is
to
be
used
as
a
platform
for
exploration
and
discussion.
All
interviews
will
be
conducted
directly
by
Harrison
Hayes’s
Principals
and
Research
Team
who
have
the
autonomy
to
probe
deeper
and
maneuver
through
unique
issues
that
arise
during
discussion
with
the
KILs
–
what
we
refer
to
as
improvisational
interviewing.
Our
Research
Team
is
able
to
select
the
most
appropriate
questions
to
ask
each
KIL
due
to
our
extensive
knowledge
and
involvement
with
the
project’s
goals.
These
interviews
are
conducted
individually,
which
allows
us
to
focus
directly
on
the
expertise
that
each
KIL
possesses.
Improvisational
interviewing
yields
valuable
qualitative
interview
data
unlike
structured
interview
surveys.
Instead
of
merely
moving
from
question
to
question,
our
Research
Team
is
able
to
adapt
based
on
KILs’
response
to
questions,
thus
obtaining
additional
insight.
To
complement
our
primary,
qualitative
Key
Innovation
Leader
(KIL)
research
we
will
concurrently
perform
secondary
research
from
syndicated,
internal,
and
public
sources.
We
believe
secondary
research
will
provide
us
with
useful
data
regarding
the
challenges
and
direction
of
new
medical
and
health-­‐related
businesses
over
the
next
10-­‐15
years.
Our
Secondary
Research
Methodology
and
its
role
in
the
project’s
outcome
is
discussed
further
detail
below.
Harrison
Hayes
believes
that
through
the
effective
marrying
of
primary
KIL
insight
and
secondary
research
–
along
with
our
partnership
with
the
Company
‘X’
project
team
–
we
can
obtain
exceptional
insight
into
the
potential
for
expansion
outside
the
United
States.
Our
research
module
begins
by
concurrently
identifying
and
recruiting
a
customized
panel
of
KILs
(Table
2-­‐Key
Innovation
Leaders)
and
developing
a
project
specific
KIL
study
guide/questionnaire.
Note:
The
KILs
ultimately,
are
our
co-­‐creators
in
the
ideation
process.

12. 12
METHODOLOGY
Table
1:
Examples
of
Key
Innovation
Leaders
(KILs)
• Clinical
Dietitians,
Nutritionists,
and
Pharmacists
• Practitioners
and
specialists
in:
o Aging
o Brain
Health
o Chronic
Illness/Rare
Diseases
o Critical
Care
Surgery
o Food
Allergy
o Gastroenterology
o Malnutrition
o Obesity
o Pediatrics
• Food
Formulation
Scientists
• Product
Innovation
Heads
at
companies
such
as
PepsiCo,
Kellogg’s,
General
Mills,
GNC,
etc.
• Regulatory
Experts
• Medical,
Nutrition,
Technology
and
Healthcare
Futurists;
Innovation;
Trends
• Life/Health
Sciences
Venture
Capital
Investors
• Academic
researchers
in
Medical
Nutrition
• Academic
researchers
in
Aging
• Academic
researchers
in
Brain
Health
• Academic
researchers
in
Chronic
Illness/Rare
Diseases
• Academic
researchers
in
Critical
Care
Surgery
• Academic
researchers
in
Food
Allergy
• Academic
researchers
in
Gastroenterology
• Academic
researchers
in
Malnutrition
• Academic
researchers
in
Obesity
• Academic
researchers
in
Pediatrics

13. 13
• Table 2: Examples of Potential Key Innovation Leaders
Person's
Name
Title/Expertise
Ann
T.
Riggs
MD,
CMD
Associate
Professor
of
Medicine,
Director,
Division
of
Long
Term
Care
Donald
W.
Reynolds
Department
of
Geriatrics,
University
of
Arkansas
for
Medical
Sciences.
In
addition
to
her
work
at
UAMS,
Riggs
is
a
consultant
for
the
Arkansas
Foundation
for
Medical
Care.
She
also
serves
on
several
national
committees
for
the
American
Medical
Directors
Association,
a
professional
organization
for
the
advancement
of
nursing
home
medicine.
Riggs'
interest
lies
in
improving
care
at
the
end
of
life,
frailty
and
nursing
home
medicine.
Chandan
K.
Sen,
PhD
Department
of
Surgery
&
Molecular
&
Cellular
Biochemistry;
focuses
on
reactive
oxygen
species
&
anti-­‐oxidant
nutrients
with
emphasis
on
tissue
injury
and
repair;
Executive
Director
of
OSU
Comprehensive
Wound
Ctr.
His
research
program
is
housed
in
the
Davis
Heart
and
Lung
Research
Institute
where
he
serves
as
a
Deputy
Director
and
the
Director
of
the
Regenerative
Medicine
Program.
Dr.
Sen's
current
research
on
tissue
injury
and
repair
is
split
into
three
programs:
stroke,
post-­‐infarction
myocardial
remodeling
and
cutaneous
wound
healing.
He
is
a
PI
of
several
projects
including
multiple
clinical
trials.
His
research
has
been
continuously
extramurally
funded
by
prestigious
agencies
such
as
five
different
institutes
of
the
National
Institutes
of
Health,
US
Department
of
Defense,
US
Department
of
Veteran
Affairs
and
the
industry.
E.
Paul
Cherniack
MD
Division
of
Geriatrics
and
Gerontology
University
of
Miami
School
of
Medicine
and
the
Miami
VA
Medical
Center.
E.
Paul
Cherniack
completed
a
study
assessing
the
effects
of
supplementation
of
vitamin
D
on
calciotropic
hormones
and
safety
in
the
same
subject
population
in
this
proposal
that
was
recently
published
in
the
Journal
of
the
American
Geriatrics
Society.
He
is
currently
a
co-­‐
investigator
on
a
project
to
determine
the
effects
supplementation
of
vitamin
D
on
the
physical
performance
of
the
elderly.
Floyd
H.
"Ski"
Chilton,
Ph.
Wake
Forest
University
Health
Sciences
(WFUHS).
Research
by
Chilton,
professor
of
physiology
and
pharmacology
at
Wake
Forest
University
School
of
Medicine,
focuses
on
the
role
that
diet
or
medical
foods
play
in
human
disease.
Chilton,
director
of
the
Center
for
Botanical
Lipids
at
Wake
Forest
Baptist
Medical
Center,
is
widely
recognized
for
his
work
on
the
role
of
fatty
acid
metabolism
in
human
diseases,
plus
the
role
that
inflammation
plays
in
so
many
diseases
such
as
cardiac,
diabetes,
arthritis.
Based
on
his
own
and
others'
research,
Chilton
is
a
major
proponent
of
the
addition
of
fiber
to
the
diet,
balancing
the
omega
fats
and
increasing
specific
families
of
polyphenols.
Frank
M
Sacks
Department
of
Nutrition,
Harvard
School
of
Public
Health
Gregory
Primus
Orthopedic
Surgeon
at
Chicago
Center
for
Sports
Medicine
Ivy
M.
Alexander,
PhD,
C-­‐ANP
Associate
Professor
at
the
Yale
University
School
of
Nursing
and
Director
of
the
Adult,
Family,
Gerontological
and
Women's
Health
Primary
Care
Specialty.
She
is
also
a
practicing
clinician
in
the
internal
medicine
department
of
the
Yale
University
Health
Services.
Dr.
Alexander
received
her
Bachelor
of
Science
in
Nursing
degree
from
the
Pennsylvania
State
University

14. 14
José
R.
Fernández
Department
of
Nutrition
Sciences
and
Clinical
Nutrition
Research
Center,
University
of
Alabama
at
Birmingham.
Dr.
Fernández
main
research
interest
is
the
identification
of
genes
that
contribute
to
racial
differences
in
obesity
and
diabetes.
He
uses
the
genetic
admixture
approach
as
a
tool
to
decompose
the
genetic,
social
and
cultural
components
underlying
racial
and
ethnic
differences.
He
is
also
interested
on
the
application
of
methods
for
QTL
mapping,
the
use
of
linear
statistical
models
to
(a)
identify
genes
in
the
population
(b)
identify
gene-­‐gene
interactions
and
(c)
identify
the
interaction
of
genes
and
environment,
and
the
use
of
statistical
approaches
to
improve
the
identification
of
genes
in
the
population.
Joseph
J
Carlson
Department
of
Food
Science
and
Human
Nutrition
Michigan
State
University.
Since
October
2005,
Joe
has
served
as
the
Director
of
the
Sports
and
Cardiovascular
Nutrition,
which
includes
the
Spartan
Nutrition
and
Performance
Program
(SNAPP).
He
is
jointly
appointed
with
MSU's
Dept.
of
Food
Science
and
Human
Nutrition.
He
received
his
degrees
from
MSU
including
a
BS
in
Nutrition/
Dietetics
(85),
Masters
(88)
and
PhD
(97)
in
Exercise
Physiology
with
a
cognate
in
Nutrition.
He
is
a
Certified
Specialist
in
Sports
Dietetics
(CSSD)
with
the
American
Dietetic
Association.
Rachelle
S.
Doody,
M.D.,
Ph.D.
Effie
Marie
Cain
Chair
in
Alzheimer's
Disease
Research
and
Professor
of
Neurology
in
the
Department
of
Neurology
at
Baylor
College
of
Medicine.
Current
research
interests
include
studies
to
understand
and
model
the
progression
of
Alzheimer's
Disease,
studies
of
clinical
heterogeneity,
and
research
and
development
of
new
medications
to
treat
Alzheimer's
Disease.
Dr.
Doody
has
served
on
the
Texas
Council
on
Alzheimer's
Disease
and
Related
Disorders,
the
Board
of
Directors
for
the
Houston
and
Southeast
Texas
Chapter
of
the
Alzheimer's
Association
and
is
listed
in
Best
Doctors
in
America.
Shawkat
Dhanani,
MD,
MPH
Director,
Geriatric
Evaluation
&
Management
Unit,
Geriatric
Research,
Education
&
Clinical
Center,
VA
Greater
Los
Angeles
Healthcare
System.
Associate
Clinical
Professor,
Division
of
Geriatric
Medicine,
UCLA
School
of
Medicine
Wilbert
S.
Aronow
MD,
FACP,
FACC,
FAHA,
FACCPAGSF,
FGSA
Clinical
Professor
of
Medicine
and
Chief,
Cardiology
Clinic.
Wilbert
S
Aronow
MD
is
Clinical
Professor
of
Medicine;
Director
Cardiology
Clinic;
and
Senior
Associate
Program
Director
and
Research
Mentor
for
the
Residency
and
Fellowship
Programs
Department
of
Medicine
Westchester
Medical
Center/New
York
Medical
College
He
received
his
MD
from
Harvard
Medical
School.
He
received
the
Distinguished
Service
Award
from
the
Society
of
Geriatric
Cardiology
in
2003
the
Joseph
T
Freeman
Award
from
the
Gerontological
Society
of
America
New
York
Medical
College
Adjunct
Professor
of
Geriatrics
and
Adult
Development
Mount
Sinai
School
of
Medicine.

15. 15
Alice
Ammerman,
PhD
School
Nutrition
Policy,
Dept.
of
Nutrition,
Schools
of
Public
Health
and
Medicine,
UNC
Chapel
Hill.
Dr.
Ammerman
is
interested
in
design
and
testing
of
innovative
clinical
and
community-­‐based
nutrition
and
physical
activity
intervention
approaches
for
chronic
disease
risk
reduction
in
primarily
low
income
and
minority
populations.
Dr.
Ammerman
has
strong
research
and
practice
collaborations
across
the
state
addressing
childhood
obesity
and
was
appointed
by
the
Lieutenant
Governor
to
serve
on
the
Childhood
Obesity
Study
Committee,
charged
with
recommending
legislative
action
around
childhood
obesity.
She
is
also
PI
of
the
Center
of
Excellence
for
Training
and
Research
Translation,
charged
with
identification,
translation,
and
dissemination
of
evidence-­‐based
interventions
for
obesity
and
cardiovascular
disease
control
and
prevention.
More
recent
research
interests
focus
on
school
nutrition
policy
associated
with
childhood
obesity,
sustainable
agriculture
as
it
relates
to
improved
nutrition,
and
social
entrepreneurship
as
a
sustainable
approach
to
addressing
public
health
concerns.
Colin
Wilborn,
PhD,
CSCS,
FISSN
Exercise
and
Sport
Nutrition
Laboratory,
Baylor
University.
Colin
is
currently
an
Associate
Professor
of
Physical
Therapy,
Dean
of
the
Graduate
School
and
Research,
&
Director
of
the
Human
Performance
Lab
at
the
University
of
Mary
Hardin-­‐Baylor.
Colin
has
published
over
200
peer
reviewed
articles,
abstracts,
and
book
chapters
on
the
effects
of
sport
supplements
and
exercise
on
body
composition,
metabolism,
and
performance.
Colin’s
professional
and
personal
interests
are
the
effects
resistance
training
and
sport
nutrition
on
health,
body
composition,
and
performance.
Nilesh
M.
Mehta,
MD
Boston
Children’s
Hospital,
Critical
Care
Nutrition
Boston,
Mass.
Dr.
Mehta
has
a
keen
interest
in
optimal
nutrition
therapy
and
its
impact
on
outcomes
in
critically
ill
children.
His
scholarly
pursuits
have
focused
on
describing
the
metabolic
response
to
stress,
energy
and
protein
metabolism,
changes
in
body
composition
and
strategies
to
optimize
nutrient
intake
in
children
with
critical
illness,
injury
and
following
surgery.
M.
Molly
McMahon,
MD
Mayo
Clinic,
Division
of
Endocrinology
Rochester,
Minn.
Dr.
McMahon
is
the
medical
director
of
adult
nutrition
support
services
at
the
Mayo
Clinic
and
the
President
Elect
of
the
American
Society
for
Parenteral
and
Enteral
Nutrition.
Charlene
W.
Compher,
PhD,
RD,
CNSC,
LDN,
FADA,
FASPEN
University
of
PA
School
of
Nursing,
Nutrition
Science
Philadelphia,
Pa.
Dr.
Compher’s
clinical
work
has
been
the
inspiration
for
her
research,
including
several
clinical
trials
that
contributed
to
the
2012
FDA
approval
of
teduglutide,
the
first
targeted
therapy
for
short
bowel
syndrome
to
reduce
intravenous
nutrition
for
these
patients.
More
recently,
Dr.
Compher
and
colleagues
compared
the
effectiveness
of
exclusive
enteral
nutrition
feeding,
partial
enteral
nutrition,
and
biological
therapy
on
Crohn’s
disease
in
children.
They
found
that
exclusive
enteral
nutrition
and
biological
therapy
had
similar
effectiveness.
Another
study
of
critically
ill
patients
found
that
higher
protein
intake
was
associated
with
improved
survival
and
faster
discharge.
Stacy
Brethauer,
MD,
FASMBS
Dr.
Brethauer
is
a
Staff
Physician
in
the
Section
of
Laparoscopic
and
Bariatric
Surgery
at
Cleveland
Clinic.
He
is
the
Director
of
Bariatric
Surgery
at
Fairview
Hospital
and
Associate
Program
Director
for
the
Advanced
Laparoscopic
and
Bariatric
Surgery
Fellowship
program.
He
currently
serves
on
the
ASMBS
Executive
Council
as
President-­‐elect.
He
is
involved
in
a
variety
of
national
committees
and
task
forces
focusing
on
quality
and
accreditation
in
bariatric
surgery.

16. 16
Deborah
Bade
Horn,
DO,
MPH,
MFOMA
Dr.
Horn
is
the
medical
director
of
the
Center
for
Obesity
Medicine
and
Metabolic
Performance
and
is
a
clinical
assistant
professor
at
the
University
of
Texas
Medical
School.
She
is
board
certified
in
family
and
general
preventive
medicine
and
is
a
Diplomate
of
the
American
Board
of
Obesity
Medicine.
In
2011,
Dr.
Horn
earned
the
Obesity
Medicine
Association’s
(OMA)
Bariatrician
of
the
Year
award.
She
currently
serves
as
the
OMA
president.
She
regularly
presents
in
a
variety
of
educational
formats
and
venues
about
physical
activity,
obesity,
and
weight-­‐related
comorbidities.
Wendy
Scinta,
MD,
MS
Dr.
Wendy
Scinta
is
a
nationally
recognized
expert
on
adult
and
childhood
obesity
treatment,
and
current
president-­‐elect
of
OMA.
She
is
a
clinical
assistant
professor
of
family
medicine
at
SUNY
Upstate,
a
Diplomat
of
the
American
Board
of
Family
Physicians,
and
a
Diplomate
of
the
American
Board
of
Obesity
Medicine.
Her
recent
awards
include
receiving
Obesity
Medicine
Clinician
of
the
Year
(OMA-­‐2012),
Physician
of
the
Year
(NY
Business
Journal-­‐2013),
and
America’s
Top
Doctors
(CRCA-­‐2014).
Dr.
Scinta’s
BOUNCE
childhood
obesity
program
has
been
researched
and
implemented
internationally.
Ethan
Lazarus,
MD
Dr.
Ethan
Lazarus
is
a
Diplomate
of
the
American
Board
of
Obesity
Medicine,
is
board
certified
by
the
American
Board
of
Family
Medicine,
and
serves
as
the
Obesity
Medicine
Association’s
delegate
for
the
American
Medical
Association
(AMA).
He
has
been
practicing
obesity
medicine
since
2004.
His
practice
focuses
on
a
multi-­‐modal
collaborative
approach
to
helping
patients
achieve
and
maintain
a
healthy
weight.
He
believes
in
evidence-­‐based
medicine
and
is
committed
to
developing
technology
that
will
allow
obesity
medicine
practices
to
track
their
interventions
and
outcomes
in
a
meaningful
way
to
prove
that
treatments
are
safe,
effective,
and
economical.
Eric
C.
Westman,
MD,
MHS,
MFOMA
Dr.
Eric
Westman
received
his
MD
from
the
University
of
Wisconsin/Madison,
completed
an
internal
medicine
residency
and
chief
residency
at
the
University
of
Kentucky/Lexington,
and
completed
a
general
internal
medicine
fellowship
at
Duke
University,
which
included
a
master’s
degree
in
clinical
research.
At
Duke
since
1990,
he
is
director
of
the
Duke
Lifestyle
Medicine
Clinic,
has
carried
out
clinical
research
and
clinical
care
regarding
lifestyle
treatments
for
obesity
and
diabetes,
and
has
more
than
90
peer-­‐reviewed
publications.
He
is
currently
the
chairman
of
the
board
of
the
Obesity
Medicine
Association
and
a
fellow
of
the
Obesity
Medicine
Association
and
The
Obesity
Society.
Krishna
Doniparthi,
MD,
FAARM,
FOMA
Dr.
Krishna
Doniparthi
is
a
diplomate
of
the
American
Board
of
Obesity
Medicine
and
is
board-­‐certified
in
family
medicine
and
functional
medicine
(Fellow).
He
did
his
residency
in
family
medicine
at
the
University
of
Alabama,
where
he
was
chief
resident.
Before
residency,
he
published
research
on
pediatric
anaplastic
thyroid
cancer
at
USUHS
in
Bethesda,
Maryland.
Besides
obesity
medicine,
his
functional
medicine
focus
is
on
lipid
membrane
therapy
for
neurological
conditions,
autoimmune,
gut
microbiome
balance,
genetic
metabolism,
and
nutrigenomics.
Gordon
Jenson,
PhD,
MD
The
University
of
Vermont
College
of
Medicine
has
announced
the
appointment
of
Gordon
L.
Jensen,
M.D.,
Ph.D.,
as
senior
associate
dean
for
research.
Jensen
will
also
serve
as
professor
of
medicine
and
professor
of
nutrition
and
food
sciences
in
the
College
of
Agriculture
and
Life
Sciences.
Active
in
research
collaborations
and
mentorship,
he
has
investigated
geriatric
nutrition
concerns,
obesity
and
function
in
older
persons,
and
nutrition
and
inflammation,
and
has
served
as
co-­‐director
of
the
Penn
State
Childhood
Obesity
Prevention
Training
Program
and
co-­‐director
of
the
Clinical
and
Translational
Science
Institute
KL2
Training
Program.

17. 17
Susan
Finn,
PhD,
RD,
FAND
Susan
Finn,
CEO
of
the
global
consultancy
Finn/Parks
&
Associates,
is
a
recognized
leader
and
a
respected
communicator
in
the
food,
nutrition
and
health
arena.
As
a
top-­‐level
advisor
to
professional
societies,
educational
institutions
and
industry,
Dr.
Finn
evaluates,
interprets
and
brings
context
to
nutrition
research
and
its
implications.
Dr.
Finn
is
uniquely
skilled
at
building
dynamic
partnerships
based
on
Mutually
rewarding
goals.
Over
the
past
several
years,
she
has
Focused
on
the
common
ground
shared
by
the
quest
for
global
food
security,
the
impact
of
innovation
and
technology,
and
the
role
of
nutrition
security
in
building
strong
societies.
Speaker
of
the
House
John
Boehner
recently
appointed
Dr.
Finn
to
the
National
Commission
on
Hunger,
which
will
assess
the
hunger
crisis
in
this
Country
and
recommend
how
government
along
with
private
and
Public
partners
can
respond.
Louise
Merriman,
MS,
RD,
CDN
Director,
Clinical
Nutrition,
New
York
Presbyterian
Hospital.
Author
of
"At-­‐
risk
and
Malnourished
Patients:
When
Does
Underfeeding
in
the
Hospital
Become
Unethical?"
Karen
W.
Albaugh,
PT,
DPT,
MPH,
CWS
Neumann
University
Kenneth
Square,
PA.
Dr.
Karen
Albaugh
is
a
PA-­‐
licensed
Physical
Therapist
and
a
board
Certified
Wound
Specialist
through
the
American
Academy
of
Wound
Management.
In
addition
to
teaching
at
Neumann
University,
she
actively
practices
as
a
Clinical
Specialist
at
Optimum
Physical
Therapy
Associates
in
West
Chester,
PA.
She
is
involved
with
the
APTA
on
various
levels,
having
served
as
Program
Chair
and
as
a
consultant
for
the
development
of
curriculum
guidelines
and
wound
care-­‐coding
initiatives.
Michael
Fullmer,
RD,
CSP,
LDN,
CNSC
Division
of
Hematology/Oncology
Nemours/Alfred
I.
duPont
Hospital
for
Children.
Shara
Rose
Bialo,
MD
Division
of
Pediatric
Endocrinology
Nemours/Alfred
I.
duPont
Hospital
for
Children.
John
Bohnsack,
MD
Pediatric
Rheumatology
and
Immunology
Primary
Children's
Medical
Center
University
of
Utah
Hospitals
and
Clinics/Shriners
Hospital
Department
of
Pediatrics
University
of
Utah
School
of
Medicine.
Dr.
Bohnsack’s
clinical
interests
include
the
evaluation
and
treatment
of
rheumatic
disorders,
autoimmune
and
auto
inflammatory
diseases
(including
recurrent
fever
syndromes)
and
primary
immune
deficiency
disorders
of
childhood
and
adolescence.
His
administrative
role
in
the
Department
includes
oversight
of
the
revenue
cycle,
Pediatric
contracting,
implementation
of
clinical
information
systems,
and
redesign
of
the
ambulatory
clinics
to
improve
patient
and
physician
satisfaction.
Allison
Brinkley,
RD,
CNSC,
LD/N
Specialty
Dietitian
Arnold
Palmer
Hospital
for
Children
Outpatient
Pulmonology
Cystic
Fibrosis
Clinic.
Wendelin
A.
Burdo-­‐Hartman,
MD
Developmental
Pediatrician
Gerber
Endowed
Chair
DeVos
Children's
Hospital
Clinical
Associate
Professor,
Pediatrics
Michigan
State
University
Wendelin
A.
Burdo-­‐Hartman,
MD
is
a
member
of
the
Section
of
Developmental
and
Behavioral
Pediatrics
at
Nationwide
Children’s
Hospital
and
an
Assistant
Professor
of
Pediatrics
at
The
Ohio
State
University
College
of
Medicine.
She
also
serves
as
the
Medical
Director
of
the
Nationwide
Children's
Hospital
Interdisciplinary
Feeding
Clinic.
Her
primary
clinical,
research
and
educational
activities
include
neurodevelopmental
disabilities
and
diseases
of
prematurity.
Christopher
C.
Chang,
MD,
PhD
Clinical
Professor
of
Medicine
in
division
of
Rheumatology,
Allergy
and
Clinical
Immunology
at
UC
Davis.

18. 18
Stephanie
A.
Chopko,
PhD
Clinical
Psychologist
Division
of
Pediatric
Behavioral
Health
Department
of
Pediatrics
Nemours/Alfred
I.
duPont
Hospital
for
Children.
Mitchell
B.
Cohen,
MD
Pediatric
Gastroenterology
Professor
of
Pediatrics
Associate
Professor
of
Internal
Medicine
Director
of
the
Program
for
Research
and
Education
in
Intestinal
Disorders
Cincinnati
Children's
Hospital.
Mitchell
Cohen,
MD,
a
national
leader
in
pediatric
medicine
and
an
internationally
renowned
specialist
in
children’s
digestive
disorders,
is
chair
of
the
UAB
Department
of
Pediatrics
in
the
University
of
Alabama
School
of
Medicine
and
physician-­‐in-­‐chief
of
Children’s
of
Alabama.
Jaclyn
Costantino,
RD,
LDN
Pediatric
Clinical
Dietitian
Nemours/Alfred
I.
duPont
Hospital
for
Children.
Jaclyn
completed
the
Sodexo
Dietetic
Internship
in
the
Philadelphia
area
with
an
emphasis
in
pediatrics.
She
started
working
at
Nemours/Alfred
I.
duPont
Hospital
for
Children
as
a
clinical
dietitian
in
December
2012.
The
divisions
she
currently
work
with
include
Gastroenterology,
Diagnostic
Referral
Services
and
General
Pediatrics;
however,
I
also
have
experience
in
Critical
Care,
Neonatology
and
Rehabilitation.
Magee
L.
DeFelice,
MD
Division
of
Pediatric
Allergy/Immunology
Department
of
Pediatrics
Nemours/Alfred
I.
duPont
Hospital
for
Children.
Maureen
F.
Edelson,
MD
Pediatric
Hematologist/Oncologist
Division
of
Hematology/Oncology
Nemours/Alfred
I.
duPont
Hospital
for
Children
Instructor
in
Pediatrics
Jefferson
Medical
College.
Jonathan
Evans,
MD
Division
of
Pediatric
Gastroenterology
and
Nutrition
Nemours
Children's
Clinic.
Nancy
Swigert,
M.A.,
CCC-­‐SLP,
BCS-­‐S
Nancy
Swigert
is
the
Director
of
Speech-­‐Language
Pathology
and
Respiratory
Care
at
Central
Baptist
Hospital
in
Lexington,
KY,
a
385-­‐bed
acute
care
facility,
accredited
by
Joint
Commission
as
a
Gold
Plus
Performance
Stroke
Center.
Additionally,
she
was
the
Coordinator
for
ASHA’s
Special
Interest
Division
13,
which
encompasses
swallowing
and
swallowing
disorders.
The
Division
has
over
5400
affiliates.
She
also
was
the
chair
of
the
Healthcare
Economics
Committee,
and
was
a
president
of
the
ASHA
Foundation
as
well
as
ASHA
President
in
1998.
She
will
serve
as
chair
of
the
Specialty
Board
for
Swallowing
and
Swallowing
Disorders
2012-­‐2014.
Nadine
Conor,
Ph.D.,
Associate
Professor
Nadine
Connor
earned
her
Ph.D.
in
Neurophysiology
at
the
University
of
Wisconsin
in
Madison
in
1997.
She
is
currently
an
Associate
Professor
at
the
University
of
Wisconsin
School
of
Medicine
and
Public
Health,
division
of
Otolaryngology-­‐Head
and
Neck
Surgery.
Her
research
interests
include
sensorimotor
integration
for
the
control
of
facial
movements;
tissue
flap
physiology;
voice
disorders;
and
aging
and
neuromuscular
function
in
the
head
and
neck.
Her
lab’s
research
program
is
directed
at
understanding
how
physiological
and
structural
properties
of
muscles,
skin,
and
the
central
and
peripheral
nervous
systems
change
with
aging,
surgery,
diseases
and
disorders,
and
how
these
changes
may
influence
properties
of
voice
production,
speech,
and
swallowing.
Her
ultimate
interest
is
the
manner
in
which
behavioral,
medical,
or
surgical
treatment
may
affect
change
in
function
and
quality
of
life.
Christy
Ludlow,
BS,
MS,
Ph.D.,
Professor
Dr.
Ludlow
is
a
Professor
at
James
Madison
University
(JMU)
in
the
Department
of
Communication
Sciences
and
Disorders
where
her
research
interests
include
manipulating
neural
control
for
dysphagia
rehabilitation.

19. 19
Jan
Lewin,
Ph.D.,
Professor
Dr.
Jan
S.
Lewin
received
her
Ph.D.
from
Michigan
State
University
in
1994.
She
is
a
Professor
in
the
Department
of
Head
and
Neck
Surgery
and
Section
Chief
of
Speech
Pathology
and
Audiology
at
The
University
of
Texas
M.
D.
Anderson
Cancer
Center.
She
is
a
national
and
international
authority
on
the
restoration
of
speech
and
swallowing
function
in
patients
with
head
and
neck
cancer.
Under
her
direction,
she
developed
the
premier
program
for
functional
rehabilitation
and
restoration
of
oncology
patients
worldwide.
Laura
Michael
Laura
Michael
earned
a
Bachelor
of
Science
degree
in
Nutrition
from
the
Ohio
State
University
and
then
trained
with
one
of
the
authors
of
the
American
Dietetic
Association’s
National
Dysphagia
Diet.
In
2011,
Laura
started
her
own
company,
Dysphagia
Supplies
Direct,
to
help
people
with
dysphagia
live
their
best
lives.
She
trains
professionals
(including
CEU
courses)
and
family
care-­‐givers
in
how
to
manage
the
food
and
beverage
modifications
necessary
using
techniques
and
products
to
meet
the
needs
of
each
unique
client.
Her
company
offers
specialty
food
products,
many
of
which
are
not
readily
available
outside
the
acute-­‐care
setting,
making
it
possible
to
receive
care
at
home,
in
a
group
home
or
other
care
setting.
Her
specialty
is
caring
for
those
with
Alzheimer’s
and
other
Dementias,
ALS,
Parkinson’s
disease,
Stroke
and
Head-­‐Neck-­‐Oral
Cancers.
She
is
a
frequent
public
speaker
to
patients,
caregivers
and
the
professionals
supporting
these
populations.
Michelle
R.
Ciucci,
PhD
Michelle
R
Ciucci,
PhD
is
an
Assistant
Professor
in
the
Department
of
Communication
Sciences
and
Disorders,
Department
of
Surgery-­‐Division
of
Otolaryngology-­‐Head
&
Neck
Surgery,
and
a
faculty
member
in
the
Neuroscience
Training
Program
at
the
University
of
Wisconsin-­‐Madison
(UW).
Dr.
Ciucci
practiced
as
a
Speech-­‐Language
Pathologist
for
a
number
of
years.
In
addition
to
these
activities,
Dr.
Ciucci
has
been
the
President
of
the
Wisconsin
Chapter
of
the
American
Parkinson
Disease
Association
for
4
years.
Dr.
Ciucci
joined
the
board
of
the
NFOSD
in
2013.
Frederick
Askari,
MD,
PhD
Associate
Professor,
Hepatology
Division
of
Gastroenterology
Director,
Wilson
Disease
Program
University
of
Michigan
Health
System.
Satish
Rao,
M.D.,
PhD
PROFESSOR
OF
MEDICINE
CHIEF,
DIVISION
OF
GASTROENTEROLOGY/HEPATOLOGY
DIRECTOR,
DIGESTIVE
HEALTH
CENTER.
His
research
interests
focus
on
the
pathophysiology
and
treatment
of
inflammatory
bowel
disease,
food
intolerance
(particularly
fructose),
constipation,
fecal
incontinence
and
visceral
pain,
particularly
esophageal
chest
pain.
He
has
pioneered
several
new
techniques
of
evaluating
esophageal,
gastric,
colonic,
and
anorectal
function,
in
particular
the
brain-­‐gut
axis,
for
which
he
has
several
patents,
and
he
has
pioneered
technique
of
biofeedback
therapy
for
dyssynergic
defecation.
Kenneth
Brown,
M.C.
Dr.
Brown
is
board
certified
in
Internal
Medicine
and
Gastroenterology.
A
native
of
Nebraska,
he
completed
his
medical
training
at
the
University
of
Nebraska
Medical
Center
and
received
his
specialty
training
at
the
University
of
Texas
Health
Science
Center
at
San
Antonio.
Dr.
Brown
is
an
active
participant
in
both
local
and
national
organizations
and
was
recently
named
one
of
D
Magazine's
Best
Doctor
in
Dallas
2008.
In
addition
to
Hemorrhoid
treatment,
he
has
a
special
interest
in
Colon
Cancer
screening
and
Irritable
Bowel
Syndrome.
Barbara
Bradley
Bolen,
Ph.D.
Clinical
Psychologist
Barbara
Bradley
Bolen,
Ph.D.
is
a
clinical
psychologist
with
a
private
practice
on
Long
Island,
New
York,
who
writes
extensively
about
IBS.
She
serves
as
the
Guide
to
Irritable
Bowel
Syndrome
for
the
web
site
About.com,
and
is
the
author
of
Breaking
the
Bonds
of
Irritable
Bowel
Syndrome
and
the
co-­‐author
of
IBS
Chat:
Real
Life
Stories
and
Solutions.

20. 20
Lucinda
A.
Harris,
M.S.,
M.D.
Asst.
Professor
of
Medicine
Consultant
Division
of
Gastroenterology
&
Hepatology
Department
of
Medicine
Mayo
Clinic
–
Scottsdale
Lucinda
A.
Harris,
MS,
MD,
is
currently
Assistant
Professor
of
Medicine,
Mayo
School
of
Medicine
and
Consultant,
Division
of
Gastroenterology
and
Hepatology,
Mayo
Clinic
Scottsdale.
She
is
Co-­‐Director
of
the
Motility
Group
there.
Prior
to
her
present
position
at
Mayo,
she
was
formerly
Associate
Professor
of
Clinical
Medicine
at
the
Weill
Medical
College
of
Cornell
University
in
New
York,
NY,
where
she
also
trained
as
a
GI
fellow.
She
has
an
active
interest
in
motility
as
evidenced
by
her
special
clinical
and
research
interests
in
IBS,
chronic
constipation
and
pelvic
floor
disorders.
As
a
result
of
her
interest
in
overlap
syndromes
she
has
an
additional
interest
in
celiac
disease.
Carol
A.
Burke,
MD,
FACG
Dr.
Burke
is
Vice
Chair
of
the
Department
of
Gastroenterology
and
Hepatology
and
holds
joint
appointments
in
the
Department
of
Gastroenterology
and
Hepatology,
Colorectal
Surgery
and
the
Taussig
Cancer
Institute
at
The
Cleveland
Clinic
Foundation
in
Cleveland,
Ohio,
where
she
serves
as
Director
of
the
Center
for
Colon
Polyp
and
Cancer
Prevention
and
Head
of
the
Section
of
Polyposis
in
the
Sanford
R.
Weiss,
MD,
Center
for
Hereditary
Colorectal
Neoplasia.
Her
area
of
clinical
and
research
interests
includes
the
prevention
of
colorectal
neoplasia
both
in
sporadic
individuals
and
those
with
the
inherited
colorectal
cancer
syndromes.
Her
research
on
the
effects
of
chemo-­‐preventive
agents
on
the
prevention
of
intestinal
neoplasia
has
been
funded
by
the
National
Cancer
Institute,
the
National
Institutes
of
Health,
and
the
ACG,
among
others.
David
A.
Greenwald,
MD,
FACG
Professor
of
Clinical
Medicine,
Albert
Einstein
College
of
Medicine
Director,
Gastroenterology
Fellowship
Program,
Montefiore
Medical
Center.
Previously,
he
was
the
Fellowship
Program
Director
in
Gastroenterology
at
Montefiore
Medical
Center/Albert
Einstein
College
of
Medicine
for
nearly
two
decades
and
was
an
Associate
Division
Director
of
the
Division
of
Gastroenterology
at
Montefiore
Medical
Center
in
the
Bronx,
New
York.
He
is
also
a
Professor
of
Clinical
Medicine
at
the
Albert
Einstein
College
of
Medicine.
He
just
completed
a
term
as
one
of
the
Medical
Directors
of
the
Advanced
Endoscopy
Center.
Mark
B.
Pochapin,
MD,
FACG
Director,
Division
of
Gastroenterology,
NYU
Langone
Medical
Center.
Clinically
interested
in
the
bacteria
of
the
gut,
their
effect
on
the
development
and
prevention
of
disease,
and
the
way
in
which
advances
in
technology
can
be
used
to
improve
our
ability
to
detect
and
treat
precancerous
and
cancerous
growths
in
the
gastrointestinal
system.
Stephen
B.
Hanauer,
MD,
FAC
Clifford
Joseph
Barborka
Professor
of
Medicine,
Northwestern
University
Feinberg
School
of
Medicine,
Medical
Director
of
the
Digestive
Health
Center,
Northwestern
Medicine.
Dr.
Hanauer
serves
as
Director
of
The
Logan
Center
for
GI
Clinical
Research
and
Co-­‐Director
of
the
Inflammatory
Bowel
Disease
Research
Center
at
the
University
of
Chicago.
He
is
a
Professor
of
Medicine
and
Clinical
Pharmacology
at
University
of
Chicago
Pritzker
School
of
Medicine.
Dr.
Hanauer
is
Editor
in
Chief
of
Nature
Clinical
Practice
Gastroenterology
&
Hepatology.
He
served
as
a
Scientific
Advisor
of
Inflammatory
Bowel
Disease
at
Ocera
Therapeutics,
Inc.
He
has
been
Chairman
of
the
Scientific
Advisory
Board
and
Member
of
the
Scientific
Advisory
Board
of
Asphelia
Pharmaceuticals,
Inc.
since
September
2008.
He
serves
as
a
Member
of
Science
Advisory
Board
of
Exagen
Diagnostics,
Inc.
and
Seres
Therapeutics,
Inc.
He
serves
as
a
Member
of
IBD
Clinical
Advisory
Board
at
Receptos,
Inc.

21. 21
Nicholas
J.
Shaheen,
MD,
MPH,
FACG
Professor
of
Medicine
and
Epidemiology
Director,
Center
for
Esophageal
Diseases
and
Swallowing
University
of
North
Carolina
School
of
Medicine.
Dr.
Shaheen
performs
extensive
clinical
and
translational
research
in
diseases
of
the
esophagus,
with
a
special
emphasis
on
pre-­‐cancerous
and
cancerous
conditions.
He
is
interested
in
developing
improved
methods
of
detecting
people
who
have
these
conditions
before
they
present
with
symptoms.
He
is
Director
for
the
Center
for
Esophageal
Diseases
and
Swallowing
at
UNC,
and
has
authored
more
than
200
papers
on
these
diseases.
Douglas
G.
Adler,
MD,
FACG
Professor
of
Medicine
Director,
Gastroenterology
Fellowship
Program
University
of
Utah
School
of
Medicine
Director
of
Therapeutic
Endoscopy,
Huntsman
Cancer
Center.
His
interests
focus
on
pancreatobiliary
disease
(disorders
of
the
pancreas,
gallbladder,
and
bile
ducts)
and
therapeutic
endoscopy,
which
is
a
procedure
using
a
lighted,
flexible
instrument,
or
endoscope,
to
reach
areas
of
the
body
that
require
treatment.
Dr.
Adler
is
also
interested
in
gastrointestinal
(GI)
cancer
and
endoscopic
therapy
for
GI
cancer
patients.
Brian
E.
Lacy,
MD,
PhD,
FACG
Professor
of
Medicine,
Geisel
School
of
Medicine
at
Dartmouth
Chief,
Section
of
Gastroenterology
and
Hepatology,
Dartmouth-­‐Hitchcock
Medical
Center.
Lacy's
clinical
and
basic
science
research
interests
focus
on
disorders
of
gastrointestinal
motility,
with
an
emphasis
on
irritable
bowel
syndrome,
dyspepsia,
gastroparesis,
acid
reflux
disease,
constipation,
intestinal
pseudo-­‐obstruction,
achalasia
and
visceral
pain.
He
is
the
author
or
co-­‐author
of
over
80
peer-­‐reviewed
articles
and
the
author
or
co-­‐author
of
numerous
textbook
chapters
on
gastrointestinal
motility
disorders
and
functional
bowel
disorders.
David
T.
Rubin,
MD,
FACG
Joseph
B.
Kirsner
Professor
of
Medicine
Section
Chief,
Gastroenterology,
Hepatology
and
Nutrition
Co-­‐Director,
Digestive
Diseases
Center.
The
University
of
Chicago
Medicine.
Dr.
Rubin
performs
clinical
research
related
to
outcomes
in
inflammatory
bowel
diseases,
with
particular
interest
in
prevention
of
cancer
associated
with
these
diseases.
He
is
also
interested
in
new
therapies
for
inflammatory
bowel
diseases;
better
screening
tools
for
colorectal
cancer,
and
the
genetics
of
inflammatory
bowel
diseases.
Maureen
Gardner,
MA,
RDN,
CSO
Clinical
Dietitian
at
Moffitt
Cancer
Center
and
an
Executive
Committee
Member
of
the
Oncology
Nutrition
Dietetic
Practice
Group.
Annette
M.
Goldberg,
MS,
MBA,
RDN,
LDN
Outpatient
Dietitian
at
Boston
Medical
Center
Cancer
Center.
Primary
role
is
to
work
with
the
team
to
identify
patients
who
are
at
high
risk
for
malnutrition
or
significant
weight
loss
and
to
work
with
those
patients
to
maintain
their
nutritional
status
during
treatment.
I’m
also
a
resource
for
aiding
with
tube
feeding,
nutritional
supplements,
diet
education,
community
activities,
and
general
counseling.
Robin
McConnell,
MS,
RD,
CSO
Robin
McConnell,
MS,
RD,
CSO,
is
the
clinical
nutrition
coordinator
at
the
JTCC
and
1
of
5
oncology
nutritionists
at
the
center
who
work
with
outpatients
in
all
stages
of
treatment
and
recovery.
As
registered
dietitian
specialists
certified
in
oncology
nutrition,
she
and
other
staff
members
at
the
John
Theurer
Cancer
Center
(JTCC)
at
Hackensack
University
Medical
Center
in
New
Jersey,
(JTCC)
deal
with
challenges
including
depression,
altered
taste,
anorexia,
surgery,
and
the
inability
to
process
food.
Their
patients
“have
tremendous
issues
with
eating,”
she
said,
and
the
problem
extends
across
the
spectrum
of
cancers
and
cancer
treatments.

22. 22
Kim
Robien,
PhD,
RD,
CSO
Associate
Professor
at
the
Milken
Institute
School
of
public
Health
at
George
Washington
University.
In
their
article
in
the
Journal
of
the
American
Dietetic
Association,
Robien
and
her
collaborators
wrote
that
the
ACS
would
update
its
nutrition
and
physical
activity
guidelines
this
year
using
a
panel
of
experts
who
look
at
available
scientific
evidence.
The
current
guidelines
focus
on
cancer
prevention,
as
do
guidelines
set
by
the
World
Cancer
Research
Fund/American
Institute
for
Cancer
Research
(WCRF/AICR).
Heather
Bell-­‐Temin
MS,
RD,
CSO
Heather
Bell-­‐Temin
is
a
Registered
Dietitian
Nutritionist
and
Certified
Specialist
in
Oncology
Nutrition.
She
received
a
bachelor’s
degree
in
food
and
nutrition
from
Florida
State
University
and
a
master’s
degree
in
nutrition
from
Louisiana
State
University.
Heather
has
been
working
in
the
field
of
nutrition
for
over
15
years
and
specializes
in
the
care
of
patients
with
gastrointestinal
diseases
and
senior
adult
patients.
Tricia
Cox
MS,
RD,
LDN,
CNSC,
CSO
Tricia
Cox
is
an
Oncology
Dietitian
at
Baylor
University
Medical
Center
and
works
specifically
with
patients
receiving
a
Blood
and
Marrow
Transplant.
She
spends
her
time
working
as
part
of
a
nutrition
management
protocol
team,
managing
nutrition
support,
teaching
cooking
classes,
and
precepting
interns.
Tricia
has
revised
and
published
chapters
on
oncology
nutrition
for
the
Texas
Academy
of
Nutrition
and
Dietetics,
the
Oncology
Nutrition
for
Clinical
Practice,
and
recently
taught
an
online
class
for
the
American
Society
for
Clinical
Oncology.
Kelay
Trentham
MS,
RDN,
CSO
Kelay
Trentham
has
worked
as
an
outpatient
oncology
dietitian
since
2004
and
is
currently
at
MultiCare
Regional
Cancer
Center
in
Tacoma,
WA.
She
works
with
both
medical
and
radiation
oncology
patients,
and
worked
with
stem
cell
transplant
patients
in
her
previous
position
at
the
Seattle
Cancer
Care
Alliance.
She
was
the
first
outpatient
dietitian
hired
at
MultiCare
Regional
Cancer
Center,
as
part
of
the
navigation
team,
to
develop
outpatient
nutrition
services
for
four
clinics.
Suzanne
Michel,
MPH,
RD,
LDN
Mrs.
Michel
is
a
registered
dietitian
and
clinical
assistant
professor
at
the
Medical
College
of
South
Carolina,
a
leading
CF
center
in
Charleston,
S.C.
Suzanne
has
more
than
30
years
of
experience
working
directly
with
people
who
have
CF.
Katherine
McDonald,
PhD,
FAIDD
Dr.
Katherine
(Katie)
McDonald
is
an
Associate
Professor
in
the
Department
of
Public
Health,
Food
Studies
and
Nutrition
in
the
Falk
College
of
Sport
and
Human
Dynamics
and
a
Faculty
Fellow
at
the
Burton
Blatt
Institute
at
Syracuse
University.
Dr.
McDonald
conducts
collaborative
research
with
community-­‐based
organizations
and
community
members
on
health,
education,
community,
and
employment
disparities
experienced
by
individuals
with
disabilities.
Diana
Dawson,
P.N.P.
Diana
Dawson
is
a
pediatric
nurse
practitioner
and
clinical
nurse
specialist
specializing
in
the
care
of
children
with
lung
conditions
as
well
as
adult
cystic
fibrosis
patients.
She
treats
patients
in
the
general
pediatric
pulmonary
clinic,
Pediatric
Asthma
Program,
and
both
the
pediatric
and
adult
cystic
fibrosis
centers.
Dawson
provides
assessment,
treatment
recommendations
and
education
for
patients,
and
helps
coordinate
their
care
at
UCSF.
She
also
provides
consultative
support
to
other
nurses
caring
for
patients
with
lung
conditions.
She
helped
develop
and
create
UCSF's
Asthma
Program
and
assists
in
medical
research
and
coordinates
the
care
of
infants
identified
through
the
California
Cystic
Fibrosis
Newborn
Screening
Program.

23. 23
Robert
G.
Martindale,
MD,
PhD
Professor
of
Surgery;
Chief
of
Gastrointestinal
and
General
Surgery;
Medical
Director
Hospital
Nutritional
Service.
Dr.
Martindale’s
primary
focus
throughout
his
professional
career
has
been
in
surgical
education
and
patient
care
in
surgery
and
nutrition.
He
has
won
numerous
teaching
awards
and
continues
to
publish
and
mentor
young
physicians
and
investigators.
In
addition
to
being
the
co-­‐editor
of
a
textbook
dealing
with
surgical
and
critical
care
nutrition,
he
is
the
author
of
well
over
200
publications,
including
peer
reviewed
articles,
review
articles,
chapters,
and
several
medical
educational
videos.
Table 3: Examples of Potential Questions for Key Innovation Leaders
(Note: Additional KIL questions will emerge from discussions with Company ‘X’)
1. What
do
you
see
as
the
major
research
breakthroughs
and/or
product
and/or
new
business
model
applications
influencing
the
development
of
medical nutrition?
In
what
specific
disease
areas?
In
what
specific
types
of
healthcare,
medicine,
device
markets?
2. Which
of
these
trends
do
you
believe
will
have
the
greatest
impact
in
the
future?
3. How do you define “medical nutrition”?
4. What do you see as the role of medical nutrition in medicine today?
Do they play a valid role in the practice of medicine? Why or why
not?
5. How large is the gap between medical nutrition and traditional
medicine? Do you see this gap narrowing? Explain.
6. What technologies currently exist outside of molecules and ingredients
that may provide a benefit to a medical nutrition supplement?
7. What do you see as the major research breakthroughs and/or product
and/or new business model applications influencing the development
of medical nutrition? In what specific disease areas? In what specific
types of healthcare, medicine, device markets?
8. What are the top five emerging nutritional and/or nutraceutical (and
related molecules/ingredients) research trends (in U.S.; global)? How
would you rank them?
9. What are the most relevant issues and challenges (past, present, future)
surrounding the use of medical nutrition currently? (in U.S.; global)?

24. 24
METHODOLOGY
Secondary
Research
&
Trend
Spotting
Harrison
Hayes
believes
that
through
the
effective
marrying
of
primary
KIL
insight
and
secondary
research
–
along
with
our
partnership
with
the
Company
‘X’
project
team
–
we
can
obtain
uncommon
insight
into
understanding
and
assessing
whitespace
opportunities
to
drive
growth
and
redefine
medical
nutrition
offerings
for
Company
‘X’.
Harrison
Hayes
proposes
to
concurrently
supplement
our
primary
research
with
secondary
research
and
trend
spotting.
By
combining
primary
and
secondary
research
we
are
able
to
gain
insight
into
consumer
attitudes,
micro
markets,
and
financial
growth
possibilities
–including
return
on
investment
trends,
and
analytical
assessments
of
consumer
products,
technology
and
business
model
trends.
Secondary
research
used
to
supplement
our
primary
research
and
trend
spotting
includes:
Syndicated
Harrison
Hayes
has
established
relationships
with
a
variety
of
syndicated
information
providers.
Publicly
Available
Harrison
Hayes
conducts
significant
market
research
within
the
public
domain.
We
have
expertise
in
identifying
key
market
data
through
journal
and
trade
publications,
online
subscription
databases,
market
research
data
hubs,
proprietary
data
sources
and
archival
research.
Internal
One
of
Harrison
Hayes’s
key
assets
is
the
market
research
previously
conducted
that
resides
“in-­‐house”.
Our
ability
to
leverage
this
data
significantly
reduces
the
time
constraints
associated
with
providing
the
required
deliverables.
Secondary
Research
Excerpt
• Further
identification
of
combined
product
and
technology
portfolios
• Further
identification
of
advancements
in
medical
nutrition (e.g.
generation of new products)
• Emerging
disruptive
business
model,
reimbursement,
supply
chain
and
related
trends
• Emerging
regulatory
(state/government)
healthcare
trends
(e.g.
barriers,
opportunities,
etc.)

25. 25
METHODOLOGY
Secondary
Research
&
Trend
Spotting
Identifying
disruptive
consumer
demand
and
receptivity
potential;
unmet
needs;
and
trending
analysis
requires
primary
and
secondary
research
to
uncover
emerging
patterns
and
business
opportunities
in
the
evolving
and
growing
market.
We
do
not
guess
trends;
we
detect,
analyze
and
evaluate
them
to
make
evidentially
supported
projections.
For
this
project,
our
challenge
is
to
evaluate
the
new
markets,
micro
markets
and
potential
partnerships.
Company
‘X’’s
proprietary
panel
of
KILs
has
significant
insight
into
the
future
state
of
medicine,
devices,
biomaterials
and
technology.
They
are
on
the
cutting
edge
of
trends
and
function
as
a
valuable
resource
for
understanding
the
future
of
the
business,
new
business
models,
products
and
platforms.
Examples
of
trends
that
we
will
seek
to
uncover
include:
• Future
medical,
life
style
and
health-­‐care-­‐related
innovations
and
medical
nutrition
innovations
• Future
US
and
global
consumer
demand
for
new
medical
nutrition
products
and
services
• Cutting
edge
approaches
to
entering
new
markets
and
related
micro
markets
• Emerging
white
space
opportunities/new
business
model
trends
• Emerging
combinatorial
innovation
and
design
opportunities
(e.g.
Internet
components,
including
software,
protocols,
languages,
and
capabilities
combined
in
ways
that
create
totally
new
innovation.)
• Emerging
patents
and
related
analysis
• Competitive
M&A
(Mergers
&
Acquisitions)
movement;
trends
Trending
research
is
an
integral
part
of
a
successful
research
initiative,
and
Harrison
Hayes
is
confident
our
trend
spotting
methods
will
provide
Company
‘X’
the
necessary
insight
into
emerging
markets;
market
dynamics
(trends
analysis);
future
consumer
healthcare,
lifestyle,
technology
and
medical
demands;
and
future
business
model,
potential
product/platform
innovation/integration
opportunities.

26. 26
METHODOLOGY
Ideation
From
our
conversation
with
Company
‘X’,
we
look
forward
to
identifying
and
exploring
new
medical
nutrition
and
health-­‐related
markets,
untapped
potential
customers,
and
new,
innovated
business
models,
products
and
platforms.
Through
our
years
of
experience,
Harrison
Hayes
has
developed
a
scientific
approach
to
ideation.
We
begin
the
ideation
segment
by
utilizing
data
from
our
front-­‐end
KIL
interviews,
secondary
research,
and
internal
brainstorming
sessions
to
deliver
new
and
exciting
business
model/proposition
ideas,
product
and
platform
concepts.
We
prefer
to
conduct
the
ideation
segment
in
an
iterative
process
between
Company
‘X’
and
Harrison
Hayes.
An
individual
iteration
consists
of
10-­‐15
different
concepts
for
discussion.
We
will
seek
to
“harvest”
one
to
three
concepts
per
iteration
for
further
examination
in
the
validation
phase.
We
will
then
present
these
concept
business
models/propositions/
products/platforms
and
jointly
discuss
their
merits
and
validity.
In
doing
so,
we
will
present
to
Company
‘X’
generally
five
to
eight
(6-­‐8)
business
model,
product
and
platform
concepts
in
each
innovation
round.
Each
new
business
model/proposition/product
and
platform
concept
consists
of
three
detailed
components:
A
f
A
After
the
initial
list
of
innovated
business
models/propositions/products
and
platform
concepts
are
presented
to
Company
‘X’,
we
will
schedule
a
conference
call
to
discuss
the
merits
and
viability
of
each
of
the
platform/product
concepts.
As
a
result
of
this
conversation,
we
will
further
refine
creative
direction
for
the
next
ideation
round.
We
will
continue
with
this
process
of
creation
and
discussion
until
we
have
jointly
agreed
to
a
list
of
six
to
eight
(6-­‐8)
exceptional,
high
potential
ideated
business
models/propositions,
platform
and
product
concepts.
Name
of
Ideated
Business
Models/Platform/Products
Ideated
name
of
Company
‘X’
business
models/propositions/platform/s
and
products
Definition
&
Description
of
Ideated
Business
Models/Platform/Products
Definition
and
detailed
description
of
ideated
Company
‘X’
business
models/propositions,
platforms
and
products/s
providing
a
vibrant
and
clear
understanding
of
the
concept.
Anticipated
Audience
Profile
for
Ideated
Business
Models/Platform/Products
Appropriate
business
models/propositions,
platforms
and
products
for
the
concept
at
hand
and
reasons
why.

27. 27
METHODOLOGY
Ideation
Ideation
Business
Model
Platform/Concept
Validation/Research
Harrison
Hayes
believes
that
when
expanding
business
models,
product
lines
and/or
introducing
new
innovations,
a
holistic
view
of
receptivity
and
validation
is
required.
Therefore,
upon
selection
of
six
to
eight
(6-­‐8)
key
business
model,
product
and
platform
concepts,
we
recommend
conducting
a
three-­‐part
quantitative
and
qualitative
research
validation
study
to
capture
all
constituents
in
the
Company
‘X’
sales
channel
in
the
US
and
abroad.
Part
1
Quantitative
Distribution/Channel
Survey
The
first
research
validation
survey
consists
of
a
100
dealers/distributors
and
purchasing
customers
(Company
‘X’
consumers
and
non-­‐consumers)
regarding
their
views
on
the
ideated
business
models,
products
and
platform
concepts.
Part
2
Quantitative
End-­‐User
Confirmation
Second,
to
further
validate
the
ideated
business
model,
product
and
platform
concepts,
we
propose
surveying
100
ultimate
end-­‐users
who
might
help
develop,
process,
distribute
and/or
consume
Company
‘X’
products
in
order
to
gain
validation
for
entering
new
markets,
and
developing
new
products.
Based
on
the
relevance
to
the
selected
ideated
business
model,
product
and
platform
concepts,
we
will
make
specific
recommendations
as
to
which
methodology
(telephone
or
internet
surveys)
would
be
most
applicable.
Harrison
Hayes
will
construct
survey
questionnaires
focused
on
validating
the
selected
ideated
business
model,
product
and
platforms
concepts
through
a
battery
of
questions
used
to
determine
the
receptivity
and
practicality
of
each
concept.
Part
3
Final
Qualitative
Key
Innovation
Leader
Confirmation
&
Combined
KIL
and
Company
‘X’
Closed
Innovation
Network
Concurrent
with
the
Quantitative
Research,
Harrison
Hayes’s
Principals
and
Market
Research
Team
will
go
back
to
a
select
group
of
Company
‘X’’s
Proprietary
KILs
(selection
based
on
their
specialties)
to
validate
the
findings
and
ideas
generated
during
the
project.
Since
these
selected
KILs
were
familiar
with
this
project
from
the
beginning,
we
believe
they
will
be
able
to
participate
in
additional
disruptive
innovation
business
model,
product,
and
platform
application
discussions,
through
which
would
be
moderated
by
Harrison
Hayes
SMEs
over
a
45
day
period
of
time.